Baxter Expands Pharmaceuticals Portfolio with New Injectable Products in the U.S.
“We are proud to offer important new options for our customers and look forward to continuing to bring new innovations to the market.”
- “We are proud to offer important new options for our customers and look forward to continuing to bring new innovations to the market.”
Product launches within Baxter’s Pharmaceuticals portfolio in the U.S. include the following. - For all products, please see full Indications, Important Risk Information and links to full Prescribing Information below.
- Baxter offers the first and only FDA-approved ready-to-use Norepinephrine in Dextrose, and now provides Norepinephrine in 4 mg/250 mL, 8 mg/250 mL and 16 mg/250 mL strengths.
- Baxter now offers Vancomycin in 500 mg/100 mL, 750 mg/150 mL, 1 g/200 mL, 1.25 g/250 mL and 1.5 g/300 mL strengths.